THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $5,088,000 | -49.0% | 687,500 | 0.0% | 0.11% | -45.7% |
| Q2 2021 | $9,983,000 | -28.3% | 687,500 | +0.7% | 0.20% | -35.2% |
| Q1 2021 | $13,932,000 | +15.6% | 682,600 | +0.6% | 0.30% | +18.8% |
| Q4 2020 | $12,052,000 | -1.1% | 678,200 | -17.7% | 0.26% | -17.2% |
| Q3 2020 | $12,183,000 | -29.9% | 824,018 | -0.5% | 0.31% | -35.2% |
| Q2 2020 | $17,384,000 | +0.3% | 828,218 | +10.4% | 0.48% | -33.5% |
| Q1 2020 | $17,333,000 | +2.2% | 750,000 | +14.5% | 0.72% | +33.8% |
| Q4 2019 | $16,963,000 | +58.3% | 655,200 | +19.1% | 0.54% | +25.5% |
| Q3 2019 | $10,714,000 | +19.3% | 550,000 | 0.0% | 0.43% | +31.4% |
| Q2 2019 | $8,982,000 | -28.0% | 550,000 | 0.0% | 0.32% | -32.4% |
| Q1 2019 | $12,469,000 | -11.4% | 550,000 | 0.0% | 0.48% | -27.6% |
| Q4 2018 | $14,075,000 | -21.7% | 550,000 | 0.0% | 0.66% | +2.0% |
| Q3 2018 | $17,969,000 | +21.4% | 550,000 | -15.7% | 0.65% | +14.2% |
| Q2 2018 | $14,801,000 | -6.5% | 652,600 | 0.0% | 0.57% | -15.6% |
| Q1 2018 | $15,826,000 | -13.0% | 652,600 | 0.0% | 0.68% | -18.3% |
| Q4 2017 | $18,201,000 | -17.5% | 652,600 | +1.3% | 0.83% | -18.9% |
| Q3 2017 | $22,064,000 | -7.7% | 644,400 | +7.4% | 1.02% | -15.7% |
| Q2 2017 | $23,904,000 | +8.2% | 600,000 | 0.0% | 1.21% | -5.3% |
| Q1 2017 | $22,092,000 | +15.5% | 600,000 | 0.0% | 1.28% | -0.4% |
| Q4 2016 | $19,128,000 | -12.0% | 600,000 | 0.0% | 1.28% | -6.1% |
| Q3 2016 | $21,744,000 | +36.9% | 600,000 | -14.3% | 1.36% | +15.9% |
| Q2 2016 | $15,883,000 | +29.9% | 700,000 | +7.6% | 1.18% | +14.7% |
| Q1 2016 | $12,229,000 | +15.7% | 650,500 | +0.9% | 1.02% | +28.0% |
| Q4 2015 | $10,572,000 | +59.7% | 645,000 | +7.1% | 0.80% | +49.2% |
| Q3 2015 | $6,621,000 | +7.0% | 602,500 | +26.8% | 0.54% | +19.1% |
| Q2 2015 | $6,185,000 | -4.7% | 475,000 | +27.0% | 0.45% | -25.7% |
| Q1 2015 | $6,489,000 | +50.0% | 374,000 | +29.0% | 0.61% | +20.0% |
| Q4 2014 | $4,327,000 | +20.7% | 290,000 | +86.5% | 0.51% | -8.7% |
| Q3 2014 | $3,584,000 | +124.8% | 155,500 | +211.0% | 0.55% | +93.7% |
| Q2 2014 | $1,594,000 | – | 50,000 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |